--- schema_version: "secwatch.filing_event.v1" accession: "0001628280-26-019789" form_type: "8-K" ticker: "SNTI" cik: "0001854270" company_name: "Senti Biosciences, Inc." filed_at: "2026-03-19T23:59:59+00:00" generated_at: "2026-05-15T09:41:23.595726+00:00" event_type: "other_material" sentiment: "neutral" materiality_score: 0.55 calibrated_materiality_score: 0.55 confidence: "high" source: SEC EDGAR --- # Senti Biosciences cuts leased space 50% to 45,955 sq ft, amends sublease with GeneFab ## Summary - Leased premises reduced from ~91,910 to ~45,955 rentable sq ft effective Sept 1, 2025. - Monthly base rent for remaining space ranges $188,311 (2025-2026) to $293,010 (2032). - Landlord may draw $2.0M from existing $2.76M letter of credit; balance drops to $760,000. - Company paid or obtained payment of $1.0M reduction fee to landlord under consent amendment. - Outstanding rent of $1,374,005 from GeneFab may be satisfied via prepayment credit or cash by Sept 1, 2026. ## SEC filing metadata - accession: 0001628280-26-019789 - form_type: 8-K - ticker: SNTI - cik: 0001854270 - company_name: Senti Biosciences, Inc. - filed_at: 2026-03-19T23:59:59+00:00 - event_type: other_material - sentiment: neutral - materiality_score: 0.55 - calibrated_materiality_score: 0.55 - confidence: high - sec_items: 1.01, 9.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1854270/000162828026019789/0001628280-26-019789-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1854270/000162828026019789/snti-20260317.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001628280-26-019789 - JSON: https://secwatch.observer/filing/0001628280-26-019789.json - Plain text: https://secwatch.observer/filing/0001628280-26-019789.txt ## Key facts - Material Agreements Senti Biosciences, Inc. amended First Amendment to Sublease with GeneFab, LLC valued at subleased premises reduced to ~45,955 rentable square feet; base rent, operating expenses, taxes and (effective 2025-09-01). - Action: amendment - Agreement: lease - Counterparty: GeneFab, LLC - Value: subleased premises reduced to ~45,955 rentable square feet; base rent, operating expenses, taxes and - Effective: 2025-09-01 source text: On March 17, 2026, the Company entered into a First Amendment to Sublease (the “Sublease Amendment”), which amended and restated that certain Sublease Agreement dated August 7, 2023 (the “Original Sublease Agreement” and the Original Sublease Agreement as amended by the Sublease Amendment, the “Amended Sublease”) by and between the Company, as sublandlord, and GeneFab, LLC (“GeneFab”) as subtenant. Pursuant to the Sublease Amendment, which was effective as of the Effective Date, the subleased premises were reduced to approximately 45,955 rentable square feet as of the Effective Date. evidence_url: https://www.sec.gov/Archives/edgar/data/1854270/000162828026019789/0001628280-26-019789-index.htm - Material Agreements Senti Biosciences, Inc. amended First Amendment to Landlord's Consent to Sublease with 1430 South Loop Owner, LLC and GeneFab, LLC valued at Landlord consented to Sublease Amendment in consideration for $1.0 million Reduction Fee (effective 2025-09-01). - Action: amendment - Counterparty: 1430 South Loop Owner, LLC and GeneFab, LLC - Value: Landlord consented to Sublease Amendment in consideration for $1.0 million Reduction Fee - Effective: 2025-09-01 source text: On March 17, 2026, the Company entered into a First Amendment to Landlord’s Consent to Sublease (the “Consent Amendment”) among the Company, the Landlord and GeneFab, which was effective as of the Effective Date. Pursuant to the Consent Amendment, the Landlord consented to the Sublease Amendment in consideration for the payment by the Company or GeneFab of $1.0 million to the Landlord (the “Reduction Fee”). evidence_url: https://www.sec.gov/Archives/edgar/data/1854270/000162828026019789/0001628280-26-019789-index.htm - Material Agreements Senti Biosciences, Inc. amended First Amendment to Lease with 1430 South Loop Owner, LLC valued at reduction of leased premises from ~91,910 to ~45,955 rentable square feet; monthly base rent reduced (effective 2025-09-01). - Action: amendment - Agreement: lease - Counterparty: 1430 South Loop Owner, LLC - Value: reduction of leased premises from ~91,910 to ~45,955 rentable square feet; monthly base rent reduced - Effective: 2025-09-01 source text: On March 17, 2026, Senti Biosciences, Inc. (the “Company”) entered into a First Amendment to Lease (the “Lease Amendment”), which amended that certain Research and Development and Laboratory Lease Agreement dated June 3, 2021 (the “Original Lease Agreement” and the Original Lease Agreement as amended by the Lease Amendment, the “Amended Lease”) by and between the Company and 1430 South Loop Owner, LLC (the “Landlord”) for the Company’s premises located at 1430 Harbor Bay Parkway, Alameda, California. Pursuant to the Lease Amendment, which is effective as of September 1, 2025 (the “Effective Date”), the Company has agreed to a reduction of the leased premises from approximately 91,910 rentable square feet to approximately 45,955 rentable square feet as of the Effective Date. evidence_url: https://www.sec.gov/Archives/edgar/data/1854270/000162828026019789/0001628280-26-019789-index.htm - Material Agreements Senti Biosciences, Inc. entered into Letter Agreement with GeneFab, LLC valued at outstanding base rent of $1,374,005 may be satisfied via cash prepayment credit for work or services (effective 2025-09-01). - Action: entry - Counterparty: GeneFab, LLC - Value: outstanding base rent of $1,374,005 may be satisfied via cash prepayment credit for work or services - Effective: 2025-09-01 source text: On March 17, 2026, the Company entered into a letter agreement with GeneFab (the “Letter Agreement”), effective as of the Effective Date. The Letter Agreement provides, among other things, that the outstanding base rent of $1,374,005 owed by GeneFab to the Company may be satisfied, in whole or in part, through a cash prepayment credit to be applied toward work or services to be performed by GeneFab for the Company under a separate arrangement, that the Company may access such prepayment credit as of the Effective Date and that any unpaid portion must be paid in immediately available funds by September 1, 2026. evidence_url: https://www.sec.gov/Archives/edgar/data/1854270/000162828026019789/0001628280-26-019789-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.